Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design
Authors:
- On behalf of the Chinese NAFLD Clinical Research Network (CNAFLD CRN)OCOn behalf of the Chinese NAFLD Clinical Research Network (CNAFLD CRN)
- 6 February 2018
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 35 (2) , 218-231
Abstract
Vitamin E is one of the most promising agents for nonalcoholic steatohepatitis (NASH) treatment, and its drug responsiveness may be closely associated with haptoglobin (Hp) genotype. However, its efficacy and safety remain unknown in China. This clinical trial of vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis (VENS) is conducted to evaluate (a) the efficacy and safety of treatment with vitamin E softgel (300 mg/day) determined from standardized histologic scoring of liver biopsies, (b) whether treatment with vitamin E improves biochemical parameters, cytokines, anthropometric parameters, controlled attenuation parameter (CAP), and transient elastography (TE) values determined by Fibroscan and health-related quality of life (SF-36), (c) whether the efficacy of vitamin E treatment is associated with the Hp genotype in nondiabetic adults with NASH.Keywords
Funding Information
- Zhejiang Medicine Co., Ltd
This publication has 40 references indexed in Scilit:
- Is It Time to Screen for the Haptoglobin Genotype to Assess the Cardiovascular Risk Profile and Vitamin E Therapy Responsiveness in Patients with Diabetes?Current Diabetes Reports, 2012
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsJAMA, 2011
- The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypesAtherosclerosis, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Haptoglobin Genotype and Renal Function Decline in Type 1 DiabetesDiabetes, 2009
- Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 GenotypeArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡Hepatology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Haptoglobin Phenotypes Differ in Their Ability To Inhibit Heme Transfer from Hemoglobin to LDLBiochemistry, 2004
- Structure-function analysis of the antioxidant properties of haptoglobinBlood, 2001